organization · Reporting owner
Differentiated Ventures Investments, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Prometheus Biosciences, Inc.
Report date March 16, 2021 · Filed March 17, 2021
Jointly reported with Point72 Biotech Private Investments, LLC, 72 Investment Holdings, LLC, COHEN STEVEN A/SAC CAPITAL MGMT LP
Section 16 reporting ended · disclosed 2021-03-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 763,327 |
Reported balance
After 2021-03-16 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-03-16 · Conversion · Acquired 763,327 · Balance 763,327 F1: The shares of the Issuer's Series D-1 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F2: The securities reported herein may be deemed to be beneficially owned by each: (i) Differentiated Ventures Investments, LLC (DVI), which is deemed the beneficial owner of shares held by Point72 Biotech Private Investments, LLC (Point72 Biotech), (ii) 72 Investment Holdings, LLC (72 IH), the sole member of DVI, deemed to have sole voting and investment control over such interest held by DVI, and (iii) Steven A. Cohen (SC), the sole member of 72 IH, deemed to have sole voting and investment control over such interest held by 72 IH. Each of SC, 72 IH, and DVI disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,848,024 |
Reported balance
After 2021-03-16 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-03-16 · Conversion · Acquired 1,084,697 · Balance 1,848,024 F3: The shares of the Issuer's Series D-2 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F2: The securities reported herein may be deemed to be beneficially owned by each: (i) Differentiated Ventures Investments, LLC (DVI), which is deemed the beneficial owner of shares held by Point72 Biotech Private Investments, LLC (Point72 Biotech), (ii) 72 Investment Holdings, LLC (72 IH), the sole member of DVI, deemed to have sole voting and investment control over such interest held by DVI, and (iii) Steven A. Cohen (SC), the sole member of 72 IH, deemed to have sole voting and investment control over such interest held by 72 IH. Each of SC, 72 IH, and DVI disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,648,024 |
Reported balance
After 2021-03-16 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2021-03-16 · Purchase · Acquired 800,000 · Balance 2,648,024 F4: Point72 Associates, LLC (the Fund) is the direct owner of 800,000 shares of Common Stock. SC may be deemed to have an indirect pecuniary interest in such shares of Common Stock as an indirect holder of interests in the Fund. |
| Series D-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-03-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-16 · Conversion · Disposed 7,633,277 · Balance 0 F1: The shares of the Issuer's Series D-1 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F5: Consist of shares of Series D-1 Preferred Stock held directly by Point72 Biotech. F2: The securities reported herein may be deemed to be beneficially owned by each: (i) Differentiated Ventures Investments, LLC (DVI), which is deemed the beneficial owner of shares held by Point72 Biotech Private Investments, LLC (Point72 Biotech), (ii) 72 Investment Holdings, LLC (72 IH), the sole member of DVI, deemed to have sole voting and investment control over such interest held by DVI, and (iii) Steven A. Cohen (SC), the sole member of 72 IH, deemed to have sole voting and investment control over such interest held by 72 IH. Each of SC, 72 IH, and DVI disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. |
| Series D-2 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-03-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-03-16 · Conversion · Disposed 10,846,968 · Balance 0 F3: The shares of the Issuer's Series D-2 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F6: Consist of shares of Series D-2 Preferred Stock held directly by Point72 Biotech. F2: The securities reported herein may be deemed to be beneficially owned by each: (i) Differentiated Ventures Investments, LLC (DVI), which is deemed the beneficial owner of shares held by Point72 Biotech Private Investments, LLC (Point72 Biotech), (ii) 72 Investment Holdings, LLC (72 IH), the sole member of DVI, deemed to have sole voting and investment control over such interest held by DVI, and (iii) Steven A. Cohen (SC), the sole member of 72 IH, deemed to have sole voting and investment control over such interest held by 72 IH. Each of SC, 72 IH, and DVI disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of the Issuer's Series D-1 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.
F2: The securities reported herein may be deemed to be beneficially owned by each: (i) Differentiated Ventures Investments, LLC (DVI), which is deemed the beneficial owner of shares held by Point72 Biotech Private Investments, LLC (Point72 Biotech), (ii) 72 Investment Holdings, LLC (72 IH), the sole member of DVI, deemed to have sole voting and investment control over such interest held by DVI, and (iii) Steven A. Cohen (SC), the sole member of 72 IH, deemed to have sole voting and investment control over such interest held by 72 IH. Each of SC, 72 IH, and DVI disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
F3: The shares of the Issuer's Series D-2 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.
F4: Point72 Associates, LLC (the Fund) is the direct owner of 800,000 shares of Common Stock. SC may be deemed to have an indirect pecuniary interest in such shares of Common Stock as an indirect holder of interests in the Fund.
F5: Consist of shares of Series D-1 Preferred Stock held directly by Point72 Biotech.
F6: Consist of shares of Series D-2 Preferred Stock held directly by Point72 Biotech.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2021 Filed Mar 17, 2021 19:47 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | ConversionSeries D-2 Preferred Stock · Derivative | 10,846,968 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021571 · doc4.xml · derivative · entry 5 Point72 Biotech Private Investments, LLC · CIK 0001850122 · Former 10% Owner Differentiated Ventures Investments, LLC · CIK 0001850121 · Former 10% Owner 72 Investment Holdings, LLC · CIK 0001832749 · Former 10% Owner COHEN STEVEN A/SAC CAPITAL MGMT LP · CIK 0000905226 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,084,697 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The shares of the Issuer's Series D-2 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F3 · price: The shares of the Issuer's Series D-2 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F3 · derivative.exercise_date: The shares of the Issuer's Series D-2 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F3 · derivative.expiration_date: The shares of the Issuer's Series D-2 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F6 · derivative.underlying_shares: Consist of shares of Series D-2 Preferred Stock held directly by Point72 Biotech. F2 · ownership.nature: The securities reported herein may be deemed to be beneficially owned by each: (i) Differentiated Ventures Investments, LLC (DVI), which is deemed the beneficial owner of shares held by Point72 Biotech Private Investments, LLC (Point72 Biotech), (ii) 72 Investment Holdings, LLC (72 IH), the sole member of DVI, deemed to have sole voting and investment control over such interest held by DVI, and (iii) Steven A. Cohen (SC), the sole member of 72 IH, deemed to have sole voting and investment control over such interest held by 72 IH. Each of SC, 72 IH, and DVI disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 19:47 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | ConversionSeries D-1 Preferred Stock · Derivative | 7,633,277 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021571 · doc4.xml · derivative · entry 4 Point72 Biotech Private Investments, LLC · CIK 0001850122 · Former 10% Owner Differentiated Ventures Investments, LLC · CIK 0001850121 · Former 10% Owner 72 Investment Holdings, LLC · CIK 0001832749 · Former 10% Owner COHEN STEVEN A/SAC CAPITAL MGMT LP · CIK 0000905226 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 763,327 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Series D-1 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Series D-1 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Series D-1 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of the Issuer's Series D-1 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F5 · derivative.underlying_shares: Consist of shares of Series D-1 Preferred Stock held directly by Point72 Biotech. F2 · ownership.nature: The securities reported herein may be deemed to be beneficially owned by each: (i) Differentiated Ventures Investments, LLC (DVI), which is deemed the beneficial owner of shares held by Point72 Biotech Private Investments, LLC (Point72 Biotech), (ii) 72 Investment Holdings, LLC (72 IH), the sole member of DVI, deemed to have sole voting and investment control over such interest held by DVI, and (iii) Steven A. Cohen (SC), the sole member of 72 IH, deemed to have sole voting and investment control over such interest held by 72 IH. Each of SC, 72 IH, and DVI disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 19:47 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | PurchaseCommon Stock | 800,000 | $19.00 | $15,200,000.00 |
DisclosureSEC source: 0001209191-21-021571 · doc4.xml · nonDerivative · entry 3 Point72 Biotech Private Investments, LLC · CIK 0001850122 · Former 10% Owner Differentiated Ventures Investments, LLC · CIK 0001850121 · Former 10% Owner 72 Investment Holdings, LLC · CIK 0001832749 · Former 10% Owner COHEN STEVEN A/SAC CAPITAL MGMT LP · CIK 0000905226 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,648,024 F4 · ownership.nature: Point72 Associates, LLC (the Fund) is the direct owner of 800,000 shares of Common Stock. SC may be deemed to have an indirect pecuniary interest in such shares of Common Stock as an indirect holder of interests in the Fund. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 19:47 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | ConversionCommon Stock | 1,084,697 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021571 · doc4.xml · nonDerivative · entry 2 Point72 Biotech Private Investments, LLC · CIK 0001850122 · Former 10% Owner Differentiated Ventures Investments, LLC · CIK 0001850121 · Former 10% Owner 72 Investment Holdings, LLC · CIK 0001832749 · Former 10% Owner COHEN STEVEN A/SAC CAPITAL MGMT LP · CIK 0000905226 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,848,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The shares of the Issuer's Series D-2 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F2 · ownership.nature: The securities reported herein may be deemed to be beneficially owned by each: (i) Differentiated Ventures Investments, LLC (DVI), which is deemed the beneficial owner of shares held by Point72 Biotech Private Investments, LLC (Point72 Biotech), (ii) 72 Investment Holdings, LLC (72 IH), the sole member of DVI, deemed to have sole voting and investment control over such interest held by DVI, and (iii) Steven A. Cohen (SC), the sole member of 72 IH, deemed to have sole voting and investment control over such interest held by 72 IH. Each of SC, 72 IH, and DVI disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 19:47 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | ConversionCommon Stock | 763,327 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021571 · doc4.xml · nonDerivative · entry 1 Point72 Biotech Private Investments, LLC · CIK 0001850122 · Former 10% Owner Differentiated Ventures Investments, LLC · CIK 0001850121 · Former 10% Owner 72 Investment Holdings, LLC · CIK 0001832749 · Former 10% Owner COHEN STEVEN A/SAC CAPITAL MGMT LP · CIK 0000905226 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 763,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series D-1 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F2 · ownership.nature: The securities reported herein may be deemed to be beneficially owned by each: (i) Differentiated Ventures Investments, LLC (DVI), which is deemed the beneficial owner of shares held by Point72 Biotech Private Investments, LLC (Point72 Biotech), (ii) 72 Investment Holdings, LLC (72 IH), the sole member of DVI, deemed to have sole voting and investment control over such interest held by DVI, and (iii) Steven A. Cohen (SC), the sole member of 72 IH, deemed to have sole voting and investment control over such interest held by 72 IH. Each of SC, 72 IH, and DVI disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.